FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 330:1308-1309 May 5, 1994 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Randomized clinical trials have shown that chemotherapy, tamoxifen, and ovarian ablation can each reduce the frequency of relapses and prolong survival among patients with operable breast cancer and ipsilateral axillary-lymph-node metastases¹. As a result, almost all such patients now receive adjuvant systemic therapy. Multiagent chemotherapy is the present treatment of choice for premenopausal women with node-positive breast cancer²; for postmenopausal women, endocrine therapy, alone or in combination with chemotherapy, is advantageous^3,4.

During the past 20 years, many schedules of adjuvant chemotherapy with a combination of cyclophosphamide, methotrexate, and fluorouracil have been evaluated in patients with breast cancer. . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Griggs, J. J., Culakova, E., Sorbero, M. E.S., van Ryn, M., Poniewierski, M. S., Wolff, D. A., Crawford, J., Dale, D. C., Lyman, G. H. (2007). Effect of Patient Socioeconomic Status and Body Mass Index on the Quality of Breast Cancer Adjuvant Chemotherapy. JCO 25: 277-284 [Abstract] [Full Text]  
• Muller, H.-J., Gleiter, C. H., Gundert-Remy, U., Melnychuk, D., Panasci, L. C., Coppin, C. M.L., Goldie, J. H., Sauter, C., Garey, J., Lehrer, S., Farkas, D. H., Umek, R. M., Morrison, B. W., Atkins, C. D., Wood, W. C., Budman, D., Henderson, I. C., Muss, H. B., Thor, A. D., Berry, D. A., Goldhirsch, A., Gelber, R. D. (1994). Adjuvant Therapy for Breast Cancer. NEJM 331: 741-746 [Full Text]  
• (1994). DOSE-RESPONSE TO ADJUVANT CHEMOTHERAPY IN BREAST CANCER. JWatch General 1994: 1-1 [Full Text]